Purpose

The objective for this clinical study is to provide FDA with clinical evidence regarding the effectiveness and safety of the AGBS + moderate intensity lifestyle modification therapy program, indwell time of the AGBS inside the stomach, and outcomes at 48 weeks.

Condition

Eligibility

Eligible Ages
Between 22 Years and 65 Years
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  1. Age ≥22 years and ≤ 65 years of age 2. BMI ≥30 kg/m2 and ≤ 40 kg/m2 3. Have signed study-specific Informed Consent Form 4. Willing to comply with study requirements, including follow-up visits 5. Documented negative pregnancy test in women of childbearing potential 6. Women of childbearing potential not intending to become pregnant for the duration of study participation. (Note: Women of childbearing potential must not be nursing at the time of treatment). 7. Fully ambulatory without any severe chronic orthopedic disease that requires reliance on crutches, walkers, or a wheelchair that could preclude exercise during the study 8. At least one unsuccessful attempt at weight loss, such as self-administered, commercial, or medically supervised lifestyle therapy program attempted within the 24 months preceding enrollment

Exclusion Criteria

  1. Unable to walk 400 meters (the length of one loop of a track and field race track) without the use of an assistance device (e.g. cane, crutches, walker, wheel chair) 2. Symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery disease 3. Pre-existing significant respiratory disease such as chronic obstructive pulmonary disease (COPD), severe sleep apnea and pneumonia 4. Previous bariatric surgery including adjustable gastric band and endoscopic sleeve gastroplasty, or likely to undergo bariatric surgery during the study period 5. Previous use of an intragastric gastric balloon 6. Current use of an intragastric device, PlenityTM and digital weight loss solutions (e.g. Noom or Calibrate) 7. History of any cancer other than non-melanoma skin cancer or papillary thyroid cancer within the last 5 years 8. Benign or malignant gastrointestinal tumors 9. History of chronic pancreatitis or acute pancreatitis within 12 months of enrollment 10. History of, or current, small bowel obstruction 11. History of severe GI motility disorder, such as severe gastroparesis 12. History of any esophageal, gastric, or small bowel surgery 13. History of, or current inflammatory bowel disease 14. Any history of intraperitoneal adhesions 15. Any history of open abdominal or gynecological surgery and/or radiation therapy to the abdomen, with the exception of cesarean sections performed at least 12 months prior to study enrollment 16. History of/or signs and symptoms of/or radiographic evidence of esophageal, gastric, or duodenal disease including, but not limited to hiatal hernia ≥5cm, inflammatory diseases, varices, severe gastroparesis, recent history of gastric or duodenal ulcers, stricture/stenosis, achalasia, severe GERD requiring maximal medical therapy, or LA Grade B, C, or D esophagitis 17. Diagnosis of autoimmune connective tissue disorder (e.g. lupus, erythematous, scleroderma) 18. Immunocompromised due to medications or medical disease or diagnosed with HIV 19. History of genetic or endocrine causes of obesity not adequately controlled by medication, including hypothyroidism 20. Type 1 diabetes or Type 2 diabetes with HgbA1c ≥ 7%, or treated with any anti-diabetic medications other than metformin 21. Significant acute and/or chronic infections 22. Severe coagulopathy defined as INR 1.5 or higher or platelet count <150, hepatic insufficiency, or cirrhosis 23. Unable or unwilling to discontinue use of aspirin and/or nonsteroidal anti-inflammatory agents (NSAIDs) at least 7 days prior to Allurion Deployment and continuing for 7 days after the Allurion Balloon is excreted 24. Currently taking the following medications (within 30 days prior to enrollment) and/or there is a need or anticipated need for these medications during the study: Excluded Medications Systemic corticosteroids Anticoagulant therapy (e.g., warfarin, dabigatran) or anti-platelet therapy Immunosuppressive therapy (e.g., azathioprine, cyclosporine) Narcotics, opiates, or benzodiazepines Insulin for treatment of diabetes Anti-seizure therapy (e.g., clonazepam, phenytoin) Anti-arrhythmics (e.g., amiodarone) 25. Inability or unwillingness to take anti-emetics during the device residence 26. Prescription or over-the- counter weight loss medication known to cause significant weight gain or weight loss within 90 days of study enrollment through study participation 27. Uncontrolled or severe psychiatric disease other than mild depression with a patient health questionnaire score of 9 or below 28. History of pulmonary embolism or deep venous thrombosis 29. Has cardiac pacemaker or other electric implantable device 30. Anemia defined as either: Hgb <11 g/dL for females, <12 g/dL for males 31. Smoking cessation (any product, including marijuana) within 3 months of enrollment or plans to quit smoking during the study 32. Documented total body weight loss of ≥ 5% anytime 6 months preceding enrollment 33. Residing in a location without access to study site medical resources 34. History of or currently active eating disorders including night eating syndrome (NES), bulimia, or binge eating disorder 35. Unwilling to refrain from any reconstructive and/or cosmetic surgery that may affect body weight during the study such as mammoplasty and lipoplasty 36. Current, or history of, illicit drug use (defined per state law) or excessive alcohol use 37. Enrolled in another investigational study that has not completed the required primary endpoint follow-up period (Note: Subjects involved in a long-term surveillance phase of another study are eligible for enrollment in this study). 38. Current Use (within the last month) of any non-smoked marijuana products that contain THC or unwilling to abstain from THC containing marijuana products during the trial 39. Any conditions that, in the opinion of each site investigator, may render the subject unable to complete the study with a likely final outcome, or lead to difficulties for subject compliance with study requirements, or could confound study data. 40. Subject is not of sufficient medical health as determined by the Investigator to participate in the study. 41. Employees/family members of Allurion Technologies or any of its affiliates or contractors 42. Immediate employees/family members of the Investigator, sub- Investigators, or their medical office or practice, or surgical, bariatric or hospital organizations at which study procedures may be performed 43. An immediate family member (by marriage or blood relationship) of another subject already enrolled in the study 44. Positive breath or stool test for H. Pylori 45. History of covid-19 with any residual symptoms 46. Known or suspected allergies to polyurethane 47. Uncontrolled high blood pressure defined as ≥160/100 mmHg with or without medications 48. Uncontrolled high cholesterol or triglycerides defined as LDL ≥190 mg/dL or triglycerides ≥500 mg/dL 49. Inability to swallow Allurion Practice Capsule

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
AGBS + Moderate Intensity Lifestyle Therapy Group
Patients randomized to treatment will receive the AGBS device
  • Device: AGBS
    The AGBS is designed to promote weight loss in individuals with obesity. The AGBS includes the Allurion Balloon, which is a temporary gastric balloon that promotes weight loss in individuals with obesity. The AGBS consists of up to 2 balloons placed during a 1-year period.
    Other names:
    • Allurion Gastric Balloon System (AGBS)
No Intervention
Moderate Intensity Lifestyle Therapy (CONTROL) Group
Patients randomized to the control arm will receive moderate-intensity lifestyle therapy.

Recruiting Locations

UT Health Science Center at Houston
Bellaire, Texas 77401
Contact:
Angielyn Rivera
713-486-1350

More Details

Status
Recruiting
Sponsor
Allurion Technologies

Study Contact

Ken Malomo
(508) 647-4000
kmalomo@allurion.com

Detailed Description

Prospective, open-label, multi-center, randomized study comparing the AGBS + moderate intensity lifestyle modification therapy program vs. moderate intensity lifestyle modification therapy program for the treatment of adults with obesity.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.